Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype

Statistical methods in cancer research. Volume I - The analysis of case-control studies.

1980 • 4,991 citations

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1980 • 544 citations

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

1985 • 459 citations

Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

1984 • 386 citations

Attributable risk percent in case-control studies.

1971 • 351 citations

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

1988 • 199 citations

Polymorphisms of Oxidation at Carbon Centers of Drugs and Their Clinical Significance

1979 • 163 citations

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1988 • 135 citations

Polymorphism of carbon oxidation of drugs and clinical implications.

1978 • 119 citations

Assessment of Methods to Identify Sources of Interindividual Pharmacokinetic Variations

1983 • 77 citations

Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation

1987 • 63 citations

A Population and Familial Study of the Defective Alicyclic Hydroxylation of Debrisoquine among Egyptians

1979 • 57 citations

Debrisoquine oxidation in an Australian population.

1986 • 37 citations

Genes Encoding Drug-Metabolizing Enzymes: Possible Role in Human Disease

1988 • 30 citations